Page 11234..10..»

Archive for the ‘Nano medicine’ Category

New Instrument Will Uncover Structure and Chemical Composition on Sub-Cell Scale – Georgia Tech News Center

Tuesday, January 12th, 2021

Science and Technology

January 11, 2021 Atlanta, GA

Click image to enlarge

Image shows a mass spectrometer and scanning electronic microscope that provide the foundation for the BeamMap system, which can simultaneously determine surface topology and chemical makeup of a biological sample.

A new imaging instrument able to simultaneously study both the surface of a biological sample and its chemical composition is the goal of a three-year, $1.2 million National Institutes of Health (NIH) research award. Combining information from analysis of the chemical composition and physical structure of the surface of cells, tissues and even individual biomolecules inside the cells could provide a new way to study tumor growth, disease progression, cell function, and other key issues.

The technology being developed, termed Beam Enabled Accurate Mapping & Molecular Analyte Profiling (BeamMap), combines data from scanning electron microscopy and a new mode of desorption electrospray ionization mass spectrometry (DESI-MS) to simultaneously determine surface topology and chemical makeup. BeamMap uses an electron beam and a focused nanospray of electrified liquid to gather the two types of information, which is correlated with help of image processing software. The research is funded by the National Institute of Healths National Institute of General Medical Sciences (NIGMS).

To make this breakthrough tool, we need to be able to provide both topological and chemical information at resolutions on the scale of micrometers and sub-micrometers to be able to discover molecular makeup and biological function at a sub-cellular level, said Andrei Fedorov, Professor and Rae S. and Frank H. Neely Chair in the George W. Woodruff School of Mechanical Engineering at the Georgia Institute of Technology. This will require simultaneous advances, and we will be pushing the limits of both imaging tools and what mass spectrometers can do.

Because of the use of mass spectrometry for molecular sensing, BeamMap will be able to characterize proteins, metabolites, and lipid chemistry without requiring an a priori knowledge of what chemical species are present. With its ability to correlate chemical information with topological information acquired with focused electron and ion-spray beams in vacuum, the new instrument is expected to provide an order of magnitude improvement in the resolution of electrospray-based techniques, with chemical imaging resolution of approximately 250 nanometers and electron microscopy topological resolution of about 50 nanometers. BeamMap should be useful in fundamental and clinical biology, medicine, analytical chemistry, and bioengineering.

Processes that are currently invisible to us could actually be seen using BeamMap, so we will have evidence for things we can only speculate about now, Fedorov said. Being able to see what is happening at the subcellular level will allow us to get a better understanding of how biological systems behave. That will allow us to create hypotheses for how cells and tissues interact with the environment, potentially leading to a whole host of new therapeutic applications.

Among the major challenges that require an innovative research approach are the creation of soft ionization and highly local sample extraction necessary for keeping the biomolecules intact and the ability to effectively deliver the charged molecules to the vacuum environment of the mass spectrometer, he said.

We will need to fine-tune the energy of the beam that sprays on the substrate to provide the resolution we need, Fedorov said. We need to extract live biomolecules and ionize them without disrupting their structure. To do this, we will have to use the softest possible ionization.

The instrument will use the electrospray technique to create charged molecules of solvent focused in a beam about 100 nanometers in diameter. As the beam of charged solvent molecules hits the surface of the biological sample, it will ablate molecules from samples surface and move them into the surrounding vacuum environment of the SEM imaging chamber. The molecules will be charged and volatilized by the impinging nano-electrospray at a precisely tuned energy input, and then be extracted for immediate analysis in the mass spectrometer.

In parallel, an electron beam that can be focused down to 10 nanometers will be scanning and profiling the structures and features of the surfaces from which the molecules are being extracted by the electrospray. Correlating data from the two beams will provide information about the chemical makeup of the cell surface, the organelles and intracellular structures being imaged topologically.

Using multiple passes of the two beams will allow removal of layers from the samples, allowing internal structures to be mapped. Fedorov said producing each image will require several minutes, the timing limited by the speed at which the samples can be moved into the mass spectrometer and analyzed.

The characterization will be done in an electron microscope vacuum chamber, with the samples on a stage that can be moved in three dimensions. The stage will also provide cooling and hydration for the living samples during the imaging process.

The idea for the instrument came from a discussion with Andrs Garca, Regents' Professor in the George Woodruff School of Mechanical Engineering and executive director of Georgia Techs Institute for Bioengineering and Bioscience. Garca studies pancreatic cells as part of research into diabetes, and plans to use information from the new technique to develop a better understanding of the disease.

BeamMap is an exciting technological advance that will provide unparalleled biological and chemical information with high spatial resolution to analyze complex biological processes, Garca said. We are very much looking forward to applying it to understand diabetes disease progression.

This research was supported by Award 1R01GM138802-01 from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the NIH.

Research NewsGeorgia Institute of Technology177 North AvenueAtlanta, Georgia 30332-0181 USA

Media Relations Contact: John Toon (404-894-6986) (jtoon@gatech.edu)

Writer: John Toon

See the original post here:
New Instrument Will Uncover Structure and Chemical Composition on Sub-Cell Scale - Georgia Tech News Center

Read More...

Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution – The Hub at Johns Hopkins

Saturday, January 9th, 2021

ByHub staff report

Philanthropist and Johns Hopkins Medicine trustee David M. Rubenstein has made a $15 million commitment to the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins to support the department's research.

Image caption: David M. Rubenstein

The gift, his second pledge of that size to the department, will establish the David M. Rubenstein Precision Medicine Center of Excellence and will deepen his support for basic science researchers focused on the development of therapeutic approaches to preserve and restore hearing. Three strategic project teams, working in collaboration with researchers across Johns Hopkins University, will explore inner ear hair cell repair, sensory neuron repair, and nanomedicine drugs and drug delivery.

Rubenstein's gift will also support core facilities for these teams, consisting of:

Additionally, funds from this gift will support an annual conference and a speaker series.

"David's initial gift has helped Johns Hopkins researchers make important discoveries in several crucial areas related to hearing and hearing loss," said Paul B. Rothman, dean of the School of Medicine and CEO of Johns Hopkins Medicine. "But there is so much more to be done in this area, and once again, David has stepped forward. We are grateful for all that his generosity has made possible so far, and we are even more excited about what this new commitment will allow us to accomplish going forward. In the end, this work will help the millions of people who struggle every day with hearing problems."

Rubenstein's earlier gift to the department, made in 2015, funded the creation of an endowment to support cross-institutional accelerator grants. Any researcher at Johns Hopkins may apply for a grant for new or existing research to further the understanding of hearing. Grant amounts vary. In FY19, a total of $800,000 was awarded to seven different research projects, plus research core support. The earlier gift also established an endowed professorship, providing critical funds in perpetuity to support a leading faculty member in research and teaching.

"David's support has enabled innovative research projects that leverage the expertise and imagination of scientists, engineers, and clinicians from across Johns Hopkins," said Paul Fuchs, the inaugural David M. Rubenstein Research Professor of OtolaryngologyHead and Neck Surgery. "This is particularly important as we move from basic discovery of molecular and cellular mechanisms, to targeting these for therapeutic benefit. Current efforts employ gene therapy to correct inherited deafness, to regenerate cochlear hair cells, or to enhance protection from acoustic trauma. Other strategies aim to re-establish lost connections from inner ear to brain, a significant contributor to noise-induced and age-related hearing loss."

To learn more about some of the advances made possible through Rubenstein's generosity and hear from the researchers, visit the Otolaryngology-Head and Neck Surgery YouTube playlist.

Rubenstein is a founder and co-executive chairman of The Carlyle Group, a global investment firm. Rubenstein is a noted philanthropist and a long-time member of the Johns Hopkins Medicine board of trustees.

"It is a privilege to support the talented and committed researchers and doctors of Johns Hopkins who are helping people suffering from hearing loss," Rubenstein said. "I am impressed with the progress made in recent years and hope this new gift will accelerate and deepen those efforts."

Read the original:
Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution - The Hub at Johns Hopkins

Read More...

COVID-19 Impact on Nanomedicine Market Size, Latest Trends, Growth and Share 2020 to 2026| Clinical Cardiology, Urology, Genetics, Orthopedics -…

Saturday, January 9th, 2021

United States of America:-The Nanomedicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Nanomedicine market size is expected to gain market growth in the forecast period of 2020 to 2026, with a CAGR of xx% in the forecast period of 2020 to 2026 and will expected to reach USD xx million by 2026, from USD xx million in 2019.

Under COVID-19 Outbreak, how the Nanomedicine Industry will develop is also analyzed in detail in COVID Impact Chapter of this report.

For Better Understanding, Download FREE Sample Copy of Nanomedicine Market Report(Including full TOC, Graphs, Sample Data, and Tables)@ https://www.marketreportexpert.com/report/Nanomedicine/36175/sample

Some of top players influencing the Global Nanomedicine market:

Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology

Note: We can provide market report in regional language too, German/French/Japanese. We have researched the situation of COVID-19 thoroughly and Our new sample has been updated to reflect COVID-19 Impact on industry trends. We also offer a 25% discount.

Market segmentation

Nanomedicine market is split by Type and by Application. For the period 2015-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Majortype, primarily split into

Pharmaceuticals and Healthcare

Major applications/end users, including

Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends.): https://www.marketreportexpert.com/report/Nanomedicine/36175/inquiry

This report examines all the key factors influencing growth of global Nanomedicine market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global Nanomedicine market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

The Nanomedicine market is analysed and market size information is provided by regions (countries).

The key regions covered in the Nanomedicine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Regional analysis is another highly comprehensive part of the research and analysis study of the global Nanomedicine market presented in the report. This section sheds light on the sales growth of different regional and country-level Nanomedicine markets. For the historical and forecast period 2015 to 2026, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Nanomedicine market.

Get Table of Content, Tables, and Figures of Nanomedicine Market Report: https://www.marketreportexpert.com/report/Nanomedicine/36175/tableofcontent

Some of the key questions answered in this report:

What will the market growth rate, growth momentum or acceleration market carries during the forecast period?Which are the key factors driving the Nanomedicine market?What was the size of the emerging Nanomedicine market by value in 2020?What will be the size of the emerging Nanomedicine market in 2026?Which region is expected to hold the highest market share in the Nanomedicine market?What trends, challenges and barriers will impact the development and sizing of the Global Nanomedicine market?What is sales volume, revenue, and price analysis of top manufacturers of Nanomedicine market?What are the Nanomedicine market opportunities and threats faced by the vendors in the global Nanomedicine Industry?

The reports conclusion leads into the overall scope of the Global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the Global Nanomedicine market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email [emailprotected]Web:-https://www.marketreportexpert.com

https://farmingsector.co.uk/

Link:
COVID-19 Impact on Nanomedicine Market Size, Latest Trends, Growth and Share 2020 to 2026| Clinical Cardiology, Urology, Genetics, Orthopedics -...

Read More...

Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – LionLowdown

Saturday, January 9th, 2021

Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/39223

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/39223

Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

MAJOR TOC OF THE REPORT

Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at: https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

https://lionlowdown.com/

See more here:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region - LionLowdown

Read More...

Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide…

Wednesday, December 16th, 2020

SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metabolic energetic capacity of motor neurons while simultaneouslyreducing oxidative stress.

As of the data cutoff (October 27, 2020), the trial was fully enrolled with a preliminary blinded assessment of the studys primary endpoint, the motor neuron number index-4 [MUNIX(4)] score, showing that more than 40% of enrolled patients with completed week 12 data experienced improvements in motor neuron function assessed by MUNIX. When compared to baseline values, the average MUNIX(4) score of the overall trial population (including both active CNM-Au8 and placebo) experienced an absolute increase in mean MUNIX(4) values. This increase exceeded the expectations of the statistical modeling on which the study was based, which predicted a linear decline in average MUNIX(4) score from study onset (Neuwirth et al. JNNP 2015). These data, while blinded, suggest that CNM-Au8 may have neuro-reparative potential in ALS patients. Clene expects to report the complete, unblinded results from the RESCUE-ALS study in 2H 2021.

Although blinded to treatment assignment, these data are encouraging. We believe Clenes breakthrough approach with the application of physics to biology via direct electron interactions within cellular systems at the nano-scale may hold the potential to revolutionize the treatment of neurodegenerative diseases such as ALS and other motor neuron diseases, said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.

Rob Etherington, President and CEO of Clene added, This blinded interim analysis suggests that CNM-Au8 is working mechanistically to address a foundational challenge common to many neurodegenerative diseases, namely that stressed or failing neurons need additional energy for their survival, repair, and improved function. Emerging MUNIX data potentially indicate preservation of motor units, which is promising. We eagerly anticipate final results and are encouraged that these blinded interim results may provide hope for ALS patients and their families as they search for new therapies to treat this devastating disease.

The presentation (CLT-23) titled, RESCUE-ALS Trial, A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in Amyotrophic Lateral Sclerosis Patients: Design and Interim Blinded Results, is available as a live e-Poster on December 10th at 12:10 12:50 pm EST at the Virtual 31st International Symposium on ALS/MND, held online (https://symposium.mndassociation.org/virtual-2020/).

About RESCUE-ALSRESCUE-ALS is a Phase 2 multi-center, randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic with ALS (within 24-months of screening or 12-months from diagnosis). Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 (30 mg) or placebo in addition to their current standard of care. Participants will receive their randomized treatment over 36 consecutive weeks during the treatment period. The objective of this study is to assess the impact of improving neuronal bioenergetics, reducing reactive oxygen species and promoting protein homeostasis with CNM-Au8 to slow disease progression in patients with ALS. In the trial, efficacy is assessed as the average change in motor neuron unit number index (MUNIX) estimated by electromyography for the abductor digiti minimi (ADM), abductor pollicis brevis (APB), biceps brachii (BB), and tibialis anterior (TA) (muscles of the hand, arm, and leg). The trial was fully enrolled with 44 participants as of the reported 27-October-2020 data cut. Baseline characteristics include [mean (SD)], MUNIX(4) score: 93.7 (45.8); FVC % predicted: 80.8 (16.3); ALSFRS-R: 38.6 (6.1); ALSSQOL-20: 3.3 (1.3), mean time from diagnosis: 4.7 (4.6) months; riluzole background treatment, 92%.

About CNM-Au8CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of pure gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, multiple sclerosis, and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.

About ALSALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About CleneClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

Forward-Looking StatementsThis press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties to be identified in the Form S-4 filed by Chelsea Worldwide (when available) relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission (SEC) made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media ContactAndrew MielachLifeSci Communications(646) 876-5868amielach@lifescicomms.com

Investor ContactBruce MackleLifeSci Advisors, LLC(929) 469-3859bmackle@lifesciadvisors.com

See original here:
Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide...

Read More...

Global Nanomedicine market 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 -…

Wednesday, December 16th, 2020

Global Nanomedicine market Industry Trends and Forecast to 2027 New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it. To build an influential report, detailed market analysis has been conducted with the inputs from industry experts. By working on a number of steps for collecting and analysing market data, this supreme market research report is prepared with the expert team. It describes various definitions and segmentation or classifications of the industry, applications of the industry and value chain structure. Businesses can obtain a complete knowhow of general market conditions and tendencies with the information and data involved in the credible Global Nanomedicine market business report. The foremost areas of market analysis such as market definition, market segmentation, competitive analysis and research methodology are looked upon very vigilantly and precisely throughout the report.

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global nanomedicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @ https://www.databridgemarketresearch.com/request-a-discount/global-nanomedicine-market

Market Segmentation:-

By Product Type

By Application

By Indication

By Modality

To comprehend Global Nanomedicine market dynamics in the world mainly, the worldwide Nanomedicine market is analyzed across major global regions.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

See the original post here:
Global Nanomedicine market 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 -...

Read More...

NHMRC awards Griffith University $4.5 million in research funding – Griffith News

Wednesday, December 16th, 2020

Key Griffith University research projects have received $4.5 million in funding from the National Health and Medical Research Council.

Announced on December 15 by the Federal Minister for Health, The Honorable Greg Hunt MP, the seven Ideas Grants projects will contribute to vital health and medical research.

Deputy Vice Chancellor (Research) Professor Mario Pinto said the funding highlights the extraordinary work conducted by the Universitys researchers in addressing major societal health challenges.

These projects have the potential to make a significant difference to peoples health and wellbeing. I extend my congratulations and appreciation to all staff who have contributed to these efforts.

More than half the funding for Griffith University was awarded to projects within theInstitute for Glycomics, withfour research projects securing $2.56 million to explore a super vaccine that tackles bothinfluenza virus andGroup A Streptococcus bacteria and other vaccine development projects that tackle other clinically important bacterial infections.

Institute Director Professor Mark von Itzstein AO said the awards cemented the Institutes reputation as a leading biomedical research institute.

Our institute is focussed on translational research outcomes that diagnose, prevent and treat diseases of global impact. These grants will significantly assist our researchers to deliver on our mission to achieve a disease-free world.

NHMRC Ideas

Dr Mehfuz Zaman, Professor Mark von Itzstein and Professor Michael Good (Institute for Glycomics) awarded $707, 717 for the project Vaccine to prevent Influenza Virus and Bacterial superinfection (Associate Professor Victor Huber, University of South Dakota).

Associate Professor Kate Seib, Professor Michael Jennings and Dr Arun Everest-Dass (Institute for Glycomics) awarded $826,490 for the project Gonococcal vaccine development guided by a cross-protective meningococcal vaccine (Dr Caroline Thng, Gold Coast Health).

Dr Freda Jen, Associate Professor Kate Seib, Professor Michael Jennings and Dr Milton Kiefel (Institute for Glycomics) awarded $526,949.6 for the project Targeting a bacterial glycol-Achilles heel to make new vaccines for Haemophilus influenzae and Neisseria gonorrhoeae.

Professor Michael Jennings, Associate Professor Thomas Haselhorst, Dr Lucy Shewell, Dr Christopher Day (Institute for Glycomics) awarded $608,425 for the project Structure and biophysical analysis aided design of novel toxoid vaccines for a major class of bacterial toxins (Prof James Paton, The University of Adelaide, Prof Mark Walker, The University of Queensland and Prof Victor Torres, New York University).

Dr David Lloyd, Dr Claudio Pizzolato, Dr David Saxby and Dr Laura Diamond (Menzies Health Institute Queensland) awarded $860, 231 for the project Osteoarthritis compass: Predicting personalized disease onset and progression with future capacity for clinical use (Dr Michelle Hall, Assoc Prof Adam Bryant University of Melbourne, Prof David Hunter, University of Sydney; Prof Juha Toyras, Dr Shekhar Chandra, Assoc Prof Craig Engstrom The University of Queensland; Dr Jurgen Fripp, CSIRO Australian e-Health Research Centre; Prof Rami Korhonen, University of Eastern Finland).

Professor Heidi Zeeman, Dr David Painter and Professor Elizabeth Kendall (Menzies Health Institute Queensland) awarded $513, 483 for the project Dimensional Attention Modelling for Neglect Detection (DIAMOND): A novel application for brain injury (Prof Julie Bernhardt, Florey Institute of Neuroscience and Mental Health).

Associate Professor Hang Ta (Queensland Micro and Nanotechnology Centre/GRIDD) awarded $523, 342 for the project Developing smart nanomedicine to enable advanced diagnosis and stimuli-responsive treatment for atherosclerosis and thrombosis (Dr Nghia Truong Phuoc, Monash University; Dr Gary Cowin, Dr Nyoman Kurniawan, Prof Zhiping Xu, The University of Queensland and Prof Karlheinz Peter, Baker Heart and Diabetes Institute).

Griffith researchers involved in research led by other institutions

NHMRC Ideas

Prof Randipsingh Bindra, Dr Mo Chen, Assoc Prof James St John, Assoc Prof Jenny Ekberg, Dr Brent McMonagle (Griffith Health) are part of a team led by Assoc Prof Jeremy Crook (University of Wollongong) awarded $805,064.45 for the project titled A wireless electric nerve-guide for peripheral nerve repair (Dr Eva Tomaskovic-Crook, University of Wollongong).

Assoc Prof Joshua Byrnes (MHIQ, Health) is part of a team led by Assoc Prof Maree Toombs (The University of Queensland) awarded $1,279,602.45 for the project titled Advancing equitable and non-discriminatory access to health services for First Nations peoples: A multidisciplinary Queensland Human Rights Act case study (Dr Shivashankar Hiriyur Nagaraj, Queensland University of Technology; Jodie Luck, Mr DanielWilliamson, Queensland Health; Mr Jed Fraser, Queensland Aboriginal and Islander Health Council; Prof Anthony Smith, Dr Claire Brolan Dr Caitlin Curtis, Dr Sandra Creamer, Prof Wendy Hoy, Dr Amelia Radke (The University of Queensland), Dr Kelly Dingli (Queensland Aboriginal and Islander Health Council); Mr Gregory Pratt (The Council of the Queensland Institute of Medical Research)

ARC Linkage 2020 Round 1

Dr Pooja Sawrikar (School of Human Services and Social Work) is part of a Western Sydney University project led by Assoc Prof Rebekah Grace awarded $387,107 for the project Upholding the right to cultural connection for children in care.

More:
NHMRC awards Griffith University $4.5 million in research funding - Griffith News

Read More...

Global Nanomedicine Market Analysis and Forecast to 2025 by Cancer Detection, Monitoring Therapy & Disease Detection – ResearchAndMarkets.com -…

Thursday, December 10th, 2020

DUBLIN--(BUSINESS WIRE)--The "Nanomedicine Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.

This report describes the global market size of Nanomedicine from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025. For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.

For the competitor segment, the report includes global key players of Nanomedicine as well as some small players.

The information for each competitor includes:

Applications Segment:

Companies Covered:

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Abbreviation and Acronyms

Chapter 3 Preface

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter 4 Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End-users

Chapter 5 Market Trend Analysis

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

Chapter 6 Industry Chain Analysis

6.1 Upstream/Suppliers Analysis

6.2 Nanomedicine Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End-users

Chapter 7 Latest Market Dynamics

7.1 Latest News

7.2 Merger and Acquisition

7.3 Planned/Future Project

7.4 Policy Dynamics

Chapter 8 Trading Analysis

8.1 Export of Nanomedicine by Region

8.2 Import of Nanomedicine by Region

8.3 Balance of Trade

Chapter 9 Historical and Forecast Nanomedicine Market in North America (2015-2025)

9.1 Nanomedicine Market Size

9.2 Nanomedicine Demand by End Use

9.3 Competition by Players/Suppliers

9.4 Type Segmentation and Price

9.5 Key Countries Analysis

9.5.1 US

9.5.2 Canada

9.5.3 Mexico

Chapter 10 Historical and Forecast Nanomedicine Market in South America (2015-2025)

10.1 Nanomedicine Market Size

10.2 Nanomedicine Demand by End Use

10.3 Competition by Players/Suppliers

10.4 Type Segmentation and Price

10.5 Key Countries Analysis

10.5.1 Brazil

10.5.2 Argentina

10.5.3 Chile

10.5.4 Peru

Chapter 11 Historical and Forecast Nanomedicine Market in Asia & Pacific (2015-2025)

11.1 Nanomedicine Market Size

11.2 Nanomedicine Demand by End Use

11.3 Competition by Players/Suppliers

11.4 Type Segmentation and Price

11.5 Key Countries Analysis

11.5.1 China

11.5.2 India

11.5.3 Japan

11.5.4 South Korea

11.5.5 Asean

11.5.6 Australia

Chapter 12 Historical and Forecast Nanomedicine Market in Europe (2015-2025)

12.1 Nanomedicine Market Size

12.2 Nanomedicine Demand by End Use

12.3 Competition by Players/Suppliers

12.4 Type Segmentation and Price

12.5 Key Countries Analysis

12.5.1 Germany

12.5.2 France

12.5.3 UK

12.5.4 Italy

12.5.5 Spain

12.5.6 Belgium

12.5.7 Netherlands

12.5.8 Austria

12.5.9 Poland

12.5.10 Russia

Chapter 13 Historical and Forecast Nanomedicine Market in MEA (2015-2025)

13.1 Nanomedicine Market Size

13.2 Nanomedicine Demand by End Use

13.3 Competition by Players/Suppliers

13.4 Type Segmentation and Price

13.5 Key Countries Analysis

13.5.1 Egypt

13.5.2 Israel

13.5.3 South Africa

13.5.4 Gcc

13.5.5 Turkey

Chapter 14 Summary for Global Nanomedicine Market (2015-2020)

Continue reading here:
Global Nanomedicine Market Analysis and Forecast to 2025 by Cancer Detection, Monitoring Therapy & Disease Detection - ResearchAndMarkets.com -...

Read More...

Medical Physics Market: Growing Incidence of Chronic Diseases in Developing Regions to Drive the Market – BioSpace

Thursday, December 10th, 2020

Medical Physics Market: Overview

Medical physics has transformed practice of diagnostic and therapeutic medicine, which relates to the use of radiation in medicine. The role of medical physicists in ensuring quality radiation therapy, improving the performance of quality medical imaging is a key factor underpinning the evolution of the medical physics market.

Research in medical physics has focused on assessing the potentially harmful effects of radiation on patients, clinicians, and healthcare staff. Strides that diagnostic and therapeutic medicine has made over the past few years have shaped the growth trajectory of the overall medical physics market. The expanding role of radiology, radiotherapy, and nuclear medicine in diagnostics and therapeutics is a case in point.

Over the years, physicists have been increasingly leaning on discovering processes, procedures, and technologies, that will expand the scope and relevance of healthcare applications. These efforts reinforce the growing outlook of the medical physics market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78049

Medical Physics Market: Competitive Analysis and Key Developments

In recent years, medical physicists are being exhorted to improve their contribution to healthcare systems world over. A number of frameworks supporting related strategies is key to offering momentum in this direction. The American Association of Physicists in Medicine (AAPM ) in 2018 devised such a framework Medical Physics 3.0 (MP 3.0) after two years of relentless deliberations to this end. This will help greatly reinvigorate the role of medical physics in patient care in general, expanding the horizon of the market.

The association has urged physicists to securitize their role in medical area, and eventually gain a comprehensive understanding of patient care. Such initiatives are helpful in boosting the prospects of the medical physics market. Experts believe that Medical Physics 3.0 (MP3.0) is likely to set the pace for sustainable excellence in medical physics, my maximizing the contribution of physicists to improvement of human health.

Over the past few years, the medical physics market has been replete with mergers and acquisitions among the healthcare system manufacturers and healthcare providers. This has helped in boosting the adoption of cutting-edge diagnostic imaging in the medical physics market.

Request for Analysis of COVID-19 Impact on Medical Physics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78049

Medical Physics Market: Key Trends

Medical physicists have been instrumental in improving the clinical efficacy and safety of wide spectrum of diagnostic and therapeutic modality. These include mammography systems, X-ray systems, computed tomography, magnetic resonance imaging, SPECT, and PET. Key end users include hospitals, academic and research institutes, ambulatory surgery centers, and diagnostic imaging centers.

The need for reducing radiation toxicity in tomotherapy and intensity modulation radiotherapy (IMRT) is boosting the medical physics market. Medical physics is a mix of scientists and healthcare and medical professional. Thus, their role in transforming human and animal health has expanded the vistas in medical physics market.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78049

In coming years, future slew of investments in the medical physics market include orthopedics, ophthalmology, medical photonics, surgery, radiogenomics, nano?medicine, dentistry, vascular medicine, and neuro?science.

Medical Physics Market: Regional Analysis

On the regional front, North America and Europe have been vastly attractive medical physics markets. These regional markets have seen the increasing trend of outsourcing of medical physics. In recent years, the role of numerous regional associations, notably in the U.S., in expanding the role of medical physicists in human health has cemented the revenue potential of the global medical physics market. Strides being made by nuclear medicine have spurred revenues in the North America medical physics market.

Pre Book Medical Physics Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=78049&ltype=S

The growing incidence of chronic diseases in developing regions such as Asia Pacific and Latin America is opening promising investment scope in these, making them fast emerging markets.

Browse More Trending by Transparency Market Research:

Injectable Benzodiazepine Market: https://www.transparencymarketresearch.com/injectable-benzodiazepine-market.html

Oncology Small Molecule Drugs Market: https://www.transparencymarketresearch.com/oncology-small-molecule-drugs-market.html

Protein A Resin Market: https://www.transparencymarketresearch.com/protein-a-resin-market.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

ContactTransparency Market Research,90 State Street, Suite 700,Albany, NY 12207Tel: +1-518-618-1030USA - Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.com/

See the original post:
Medical Physics Market: Growing Incidence of Chronic Diseases in Developing Regions to Drive the Market - BioSpace

Read More...

Joseph DeSimone wins Harvey Prize in Science and Technology | The Dish – Stanford University News

Thursday, December 10th, 2020

by Crista Leigh Farrell on December 4, 2020 4:24 pm

JOSEPH DESIMONE, the Sanjiv Sam Gambhir Professor in Translational Medicine and professor of chemical engineering, has been named the recipient of the 2019-20 Harvey Prize in science and technology in recognition of contributions in materials science, chemistry, polymer science and technology, nanomedicine, and 3D printing.

Joseph DeSimone

The Harvey Prize, the highest honor of the Technion-Israel Institute of Technology, recognizes breakthroughs in research that benefit humanity. The prize administrators said DeSimones work is a model for combining basic scientific discoveries with developments of industrial technologies that have a significant influence.

It is incredibly humbling to be selected for the Harvey Prize, said DeSimone. I have been fortunate in my career to work with brilliant students and colleagues to make advances in science and technology toward improving the human condition, and this is a tremendous honor and testament to our work together.

DeSimone, who joined the Stanford faculty in September, holds faculty appointments in the Department of Radiology, the Department of Chemical Engineering and, by courtesy, the Graduate School of Business. He previously held a joint appointment in chemistry and chemical engineering at the University of North Carolina at Chapel Hill and North Carolina State University.

An author of more than 350 scientific articles and an inventor on more than 200 issued patents, DeSimone is known for advances rooted in polymer science that have spawned new technologies and areas of research, as well as for translating discoveries made in his laboratory to the marketplace.

In the 1990s, he and students invented an environmentally friendly process for synthesizing high-performance plastics without the use of hazardous solvents. In 2004, DeSimone and his team invented a breakthrough nanoparticle fabrication process, leading to the launch of multiple medical products in clinical trials. In 2015, he and colleagues reported a breakthrough advance in polymer 3D printing, which led DeSimone to co-found Carbon, a company whose technology has enabled cutting-edge products in such industries as footwear, dental, medical, automotive and aerospace.

DeSimone is one of only 25 people elected to all three branches of the U.S. national academies (Sciences, Engineering and Medicine). In 2016, President Obama presented him with the National Medal of Technology and Innovation.

DeSimone joins other Stanford faculty members as a winner of the Harvey Prize, including RICHARD ZARE, DONALD KNUTH, ROGER KORNBERG, KARL DEISSEROTH and CARLA SHATZ.

DeSimone will receive the prize at the Technion in Haifa, Israel, in June if pandemic conditions permit.

Follow this link:
Joseph DeSimone wins Harvey Prize in Science and Technology | The Dish - Stanford University News

Read More...

Cancer Nanomedicine Market to Build Excessive Revenue at Healthy Growth rate at 12.50% up to 2027 – PharmiWeb.com

Friday, December 4th, 2020

A new research document is added in DBMR database of 350 pages, titled as Global Cancer Nanomedicine Market Size, Share, Growth, Trends, Industry By Type (Inorganic Nanoparticles, Organic Nanoparticles), Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents), Mechanism (Targeting Tumor Cells, Nanocarrier Drug Complex, Drug Release Systems), Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others), Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI)), Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III) Country and Forecast with detailed analysis, Competitive landscape, forecast and strategies. Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention. The identification of hot and emerging players is completed by profiling 50+ Industry players; some of the profiled players are Alnylam Pharmaceuticals, Inc., Amgen Foundation, Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca, Cadila Pharmaceuticals, etc. The study conducted for Cancer Nanomedicine industry also analyses the market status, size, share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors with the help of SWOT analysis and Porters Five Forces Analysis.

Download Free Sample (350 Pages PDF, Full TOC, List of Tables & Figures, and Chart) Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-nanomedicine-market

Data Bridge Market Research analyses the Cancer Nanomedicine Market to grow at a CAGR of 12.50% in the forecast period. The growing usages of nanomedicine in drug delivery technology will further create various opportunities for the growth of the market.

The Cancer Nanomedicine Market report encompasses the general idea of the global Cancer Nanomedicine market including definition, classifications, and applications. Further, it includes the all-inclusive comprehension of several factors such as drivers, constraints, and major micro markets. The report is a wide-ranging source of widespread facts and figures for business strategists as it offers the historical &futuristic data such as demand & supply data, cost, revenue, profit, supply chain value, and so on. Furthermore, it entails the key market features, comprising production, revenue, price, capacity, gross margin, market share, consumption, gross, production rate, demand/supply, cost, capacity utilization rate, export/import, and CAGR (compound annual growth rate). In addition the report encompasses global Cancer Nanomedicine market segmentation on the basis of diverse facets like product/service type, application, technology, end-users, and major geographic regions North America, Europe, Asia-Pacific and Latin America. Apart from this, the researcher market analyst and experts present their outlook or insights of product sales, market share, and value along with the possible opportunities to grow or tap into in these regions.

Overview:

Surging volume of patients suffering from cancer, and other chronic disorders, increasing number of geriatric population across the globe, increasing development of nanotechnology-based drugs as well as therapies, adoption of advanced technologies are some of the factors which will likely to enhance the growth of the cancer nanomedicine market in the forecast period of 2020-2027. On the other hand, surging levels of investment on research and development activities along with introduction of advanced diagnostics procedure which will further bring immense opportunities for the growth of the cancer nanomedicine market in the above mentioned forecast period.

Low rate of adoption along with increasing side effects associated with the consumption of nanoparticles, stringent regulatory framework for approvals of drugs are acting as market restraints for the growth of the cancer nanomedicine market in the above mentioned forecast period.

According to this report Global Cancer Nanomedicine Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Cancer Nanomedicine Market includes comprehensive information derived from depth study on Cancer Nanomedicine Industry historical and forecast market data. Global Cancer Nanomedicine Market Size To Expand moderately as the new developments in Cancer Nanomedicine and Impact of COVID19 over the forecast period 2020 to 2027.

To Understand How Covid-19 Impact Is Covered In This Report, Get Free Covid-19 Sample @ https://www.databridgemarketresearch.com/covid-19-impact/global-cancer-nanomedicine-market

Cancer Nanomedicine Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Cancer Nanomedicine Market report is helpful for strategists, marketers and senior management, And Key Players in Cancer Nanomedicine Industry.

Key Segmentation:

By Type (Inorganic Nanoparticles, Organic Nanoparticles)

By Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents)

By Mechanism (Targeting Tumor Cells, Nanocarrier Drug Complex, Drug Release Systems)

By Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others)

By Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI))

By Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III)

Leading Players operating in the Cancer Nanomedicine Market are:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@ https://www.databridgemarketresearch.com/covid-19-impact/global-cancer-nanomedicine-market

The Cancer Nanomedicine market report also entails the vigorous evaluation about the growth plot and all opportunities &risk related to of global Cancer Nanomedicine market during the forecast period. In addition, the report comprises the key events and most recent innovations in the industry together with the prospective trends technological progresses within the global Cancer Nanomedicine market that can impact its expansion graph. Entailing the pivotal data on the markets statistics and dynamics, the report will serve as a valued asset in term of decision-making and guidance for the businesses and companies already active within industry or looking forward to enter into it.

Global Cancer Nanomedicine Market Scope and Market Size

Cancer nanomedicine market is segmented on the basis of type, agent type, mechanism, cancer type, imaging technique, and phase. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, cancer nanomedicine market is segmented into inorganic nanoparticles, and organic nanoparticles. Inorganic nanoparticles have been further segmented into synthesis of gold nanoparticle. Organic nanoparticles have been further segmented into polymeric nanoparticle, and lipid organic nanoparticles.

On the basis of agent type, cancer nanomedicine market is segmented into diagnostic agents, therapeutic agents, and drug delivery agents. Diagnostic agents have been further segmented into cancer biomarkers, diagnostic device and nanoprobes, and quantum dots. Diagnostic device and nanoprobes have been further sub segmented into biosensors, and microarrays. Therapeutic agents have been further segmented into photodynamic therapy, and photo thermal therapy.

Based on mechanism, cancer nanomedicine market is segmented into targeting tumor cells, nanocarrier drug complex, and drug release systems. Targeting tumor cells have been further segmented into passive targeting, and active targeting. Nanocarrier drug complex have been further segmented into liposomes, dendrimers, micelles, and inorganic nanocarriers.

On the basis of cancer type, cancer nanomedicine market is segmented into breast cancer, pancreatic cancer, brain cancer, lung cancer, and others.

Based on imaging technique, cancer nanomedicine market is segmented into positron emission tomography, single photon emitted tomography, and magnetic resonance imaging (MRI).

Cancer nanomedicine market has also been segmented based on the phase into research, preclinical, phase-I, phase-I/II, phase-II, and phase-III.

Geographically, the following regions together with the listed national/local markets are fully investigated:

For More Information or Query or Customization before Buying, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-nanomedicine-market

Reason to Buy

Access Full Report Directly @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-cancer-nanomedicine-market

Also, Research Report Examines:

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the global Cancer Nanomedicine Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product

Competition by Company: Here, the competition in the Worldwide Cancer Nanomedicine Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Cancer Nanomedicine Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Cancer Nanomedicine Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Cancer Nanomedicine Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Cancer Nanomedicine Market.

Market Forecast:Here, the report offers a complete forecast of the global Cancer Nanomedicine Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Browse Complete Report Details @ https://www.databridgemarketresearch.com/reports/global-cancer-nanomedicine-market

Its vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

Our Others Reports:

Online Testing Software Market Trends, Size, Growth Insight, Industry Share, Emerging Technologies by ProProfs, QuizWorks, ExamSoft, EDBASE, Testment

Health Surveillance Systems Market Size, Trends, Future Growth, Latest Technology, Innovation With Competitive Analysis by Top Players-Avigilon, Schneider Electric, Cisco, Tyco Integrated Security, Nedap N.V., ADT

Hyperhidrosis Treatment Market Size, Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by COVID-19 Impact Analysis 2027

Head Mirror Market Analysis with Top Trends, Size, Share, Leading Companies, Key Regions, Segments, Mergers and Foreseen By DBMR Till 2027

About Data Bridge Market Research, Private Ltd

Data Bridge Market ResearchPvtLtdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

We provide a variety of services such as market verifiedindustry reports, technology trend analysis, Formative market research,strategic consulting, vendor analysis, production and demand analysis, consumer impact studies among many others.

Contact Us

US: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475

Email corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Read more here:
Cancer Nanomedicine Market to Build Excessive Revenue at Healthy Growth rate at 12.50% up to 2027 - PharmiWeb.com

Read More...

Sensing the body at all scales – MIT News

Friday, December 4th, 2020

Sensors that track everything from infection in the lungs to WiFi usage on a busy university campus are poised to enhance our understanding of, and approach to improving, human health at many levels a trend that has been accelerated by the challenges of the Covid-19 pandemic, researchers and experts said at the 2020 SENSE.nano Symposium.

Videos from the event are now available online, so anyone can view the presentations and panel discussions featuring leaders from research and industry, representatives of MIT-launched startup companies, and current MIT graduate students.

Held online earlier this semester, the symposium offered a glimpse at how sensing technologies are being used to sense and quantify life at all scales, from subcellular up to large populations. It was the fourth annual meeting organized by SENSE.nano around significant themes relevant to disciplines and industries with a focus on sensors, sensing systems, and sensing technologies.

Delivering SENSE.nano as a virtual, online event permitted more than 600 individuals from 250 organizations to join us for the three half-days of the symposium, says Vladimir Bulovi, founding faculty director of MIT.nano and Fariborz Maseeh Professor of Emerging Technology. Over 80 percent of attendees were from industry, fulfilling our goal of relating academic discoveries to practitioners who can broadly scale these ideas.

Professor Elazer Edelman, director of the Institute for Medical Engineering and Science and Edward J. Poitras Professor in Medical Engineering and Science at MIT, gave the opening keynote on the first day of the 2020 SENSE.nano Symposium.

See the full agenda and watch videos of the speakers and sessions.

The event featured sessions on sensing at four levels: cell and subcellular, organs, body systems, and populations. The focus was on life as a system. The functions of the body and how we interact as human beings was celebrated across the scales at SENSE.nano 2020, says Brian W. Anthony, associate director of MIT.nano and faculty lead for the Industry Immersion Program in Mechanical Engineering. The SENSE event helped to highlight what is happening at these different scales, made explicit some connections across research domains, and hopefully also made explicit some opportunities.

Several of the presentations focused on applications for the current pandemic. Speakers discussed rapid antigen detection for infectious pathogens, detecting Covid-19-related changes in the voice using mobile phones, and understanding how pandemic misinformation propagates through social media, among other topics. One panel discussion offered insights into how the pandemic is affecting workspace design, clinical testing, and child development; another panel discussion offered insight into unique needs and opportunities for commercial innovations.

Elazer Edelman, director of the MIT Institute for Medical Engineering and Science (IMES) and keynote speaker on day one of the symposium, offered a historical perspective on sensing the body through the lens of his care for a cardiovascular patient who developed Covid-19. From Leonardo da Vincis glass models of heart circulation to the 19 pieces of equipment collecting data from the cardiovascular patients hospital bed, health care has been transformed by a marriage between medicine and science and engineering technology at all scales that has actually changed our lives, Edelman said.

Researchers working at the cutting edge of sensing technology must commit to sharing their findings, cautioned Edelman, who also serves as the Edward J. Poitras Professor in Medical Engineering and Science at MIT. The most important thing, I think, is to realize that engineers like us, scientists like us, clinicians like us, have a responsibility to the community, not simply to the clinic or the hospital. The most important thing we can do, therefore, is get all of our technology as quickly as possible out into the general population.

Digital technology is finally becoming mature enough and is giving us the tools to revolutionize how healthcare will be delivered, said Brendan Cronin, director of Digital Healthcare Group at Analog Devices and keynote speaker on day two of the symposium. Nano sensors will be used to diagnose illness faster and be used to invent new medicine in the case of synthetic biology, smart devices will routinely monitor our bodies and the environment and help manage our disease in a semi- or autonomous way, [and] doctors will routinely use digital tools to predict acute events rather than react to them, he said.

Sensing technologies face many of the same challenges of acceptance, equity, and ease of use that are found throughout health care, researchers suggested in another panel discussion. Sensors and sensing systems need to be developed with guidance from users on exactly what information or decisions they need to make with this data, while taking advantage of ubiquitous technologies such as mobile phones, they noted. Speakers also cautioned against developing technologies and systems that replicate the biases against people of color and women that have led to unequal care in the past.

The symposium was sponsored by MIT.nano, the MIT Industrial Liaison Program, MIT Institute for Medical Engineering and Science, and the MIT Clinical Research Center.

Read the original here:
Sensing the body at all scales - MIT News

Read More...

Healthcare Nanotechnology (Nanomedicine) Market Research Report with Revenue, Gross Margin, Market Share and Future Prospects till 2026 – The Market…

Friday, December 4th, 2020

The Healthcare Nanotechnology (Nanomedicine) Market grew in 2019, as compared to 2018, according to our report, Healthcare Nanotechnology (Nanomedicine) Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Healthcare Nanotechnology (Nanomedicine) Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Healthcare Nanotechnology (Nanomedicine) Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-healthcare-nanotechnology-(nanomedicine)-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Healthcare Nanotechnology (Nanomedicine) Market is analysed based on product types, major applications and key players

Key product type:NanomedicineNano Medical DevicesNano DiagnosisOther

Key applications:AnticancerCNS ProductAnti-infectiveOther

Key players or companies covered are:AmgenTeva PharmaceuticalsAbbottUCBRocheCelgeneSanofiMerck & CoBiogenStrykerGilead SciencesPfizer3M CompanyJohnson & JohnsonSmith & NephewLeadiant BiosciencesKyowa Hakko KirinShireIpsenEndo International

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-healthcare-nanotechnology-(nanomedicine)-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Healthcare Nanotechnology (Nanomedicine) Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Healthcare Nanotechnology (Nanomedicine) Market?4. What is the likely market forecast & how will be Healthcare Nanotechnology (Nanomedicine) Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Healthcare Nanotechnology (Nanomedicine) Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

Visit link:
Healthcare Nanotechnology (Nanomedicine) Market Research Report with Revenue, Gross Margin, Market Share and Future Prospects till 2026 - The Market...

Read More...

Technion Harvey prize in science awarded to Israeli, American professors – The Jerusalem Post

Friday, December 4th, 2020

Technion's Harvey prize in Chemical Engineering and Medical Sciences for 2019-2020, one of its most prestigious awards, went to Professor Joseph DeSimone of Stanford University and Professor Raphael Mechoulam of the Hebrew University, according to a Wednesday press release from the university.

In 2016, DeSimone was recognized by US President Barack Obama for his achievements and leadership in innovative technology.

Mechoulam, of the School of Pharmacology in the Faculty of Medicine at the Hebrew University of Jerusalem, was given the award for his innovative research into the components, mechanisms of action, and implications for human health of the cannabinoid system. Born in Bulgaria in 1930, Mechoulam immigrated to Israel and joined the Weizmann Institute in 1960, later becoming a professor at the Hebrew University. Mechoulam is the first researcher to have isolated the psychoactive part of cannabis ,called THC (Tetrahydrocannabinol), and mapped its structure and its major elements, Cannabidiol, CBD, which is increasingly used for medicinal purposes.

Mechoulam's long history of achievement was also recognized, as he won the Israel Prize in Exact Sciences Chemistry (2000) and the Kolthoff Prize in Chemistry from the Technion. The Jerusalem Post also recognized him as one of its most 50 influential Jews.

The Harvey Prize is awarded each year for outstanding achievements in a wide variety of fields, including science and technology, human health, and contributions to humanity. Beyond the $75,000 prize, the award has become a good indicator for the Nobel Prize, with some 30% receiving both.

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });

See the original post:
Technion Harvey prize in science awarded to Israeli, American professors - The Jerusalem Post

Read More...

Cancer Nanomedicine Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by Forecast 2026 |…

Friday, December 4th, 2020

Global Cancer Nanomedicine Market Survey Research Report

The Global Intelligence Insights added a new report Global Cancer Nanomedicine Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 2024 in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting.

Market Overview:

Cancer Nanomedicine Market to grow from USD 761.85 billion in 2016 and reach USD 918.74 billion by 2020, growing at a CAGR of 4.8% during the forecast period.

The global Cancer Nanomedicine Market report offers a complete overview of the Cancer Nanomedicine Market globally. It presents real data and statistics on the inclinations and improvements in global Cancer Nanomedicine Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Cancer Nanomedicine Market report elaborates the crucial data along with all important insights related to the current market status.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Cancer Nanomedicine market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @ https://www.globalintelligenceandinsights.com/request-sample-1004167

Top Key Players: Abraxis BioScience,Access Pharmaceuticals,Alnylam Pharmaceuticals,Arrowhead Research,BIND Biosciences,Epeius Biotechnologies,Nanobiotix,NanoCarrier,Nippon Kayaku,Samyang,Takeda Pharmaceutical

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Cancer Nanomedicine market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Market Dynamics:

The report analyzes the factors impacting the growth and the current market trends influencing the global Cancer Nanomedicine market. Detailed pricing information with ex-factory prices of various products by key manufacturers form a crucial part of the report. Competition analysis, along with regional government policies affecting the Cancer Nanomedicine market provides a detailed overview of the current status and prospects of the market. The impact of the ever-growing global population, coupled with technological advancements affecting the global Cancer Nanomedicine market is also covered in the report.

Drivers & Constraints:

The report provides extensive information about the factors driving the global Cancer Nanomedicine market. Factors influencing the growth of the Cancer Nanomedicine market, along with technological advancements, are discussed extensively in the report. The current restraints of the market, limiting the growth and their future impact are also analyzed in the report. The report also discusses the impact of rising consumer demand, along with global economic growth on the Cancer Nanomedicine market.

Regional Segment Analysis:

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Cancer Nanomedicine Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Cancer Nanomedicine Market?

What are the key market trends impacting the growth of the Global Cancer Nanomedicine Market?

What are the challenges to market growth?

Who are the key vendors in the Global Cancer Nanomedicine Market?

What are the market opportunities and threats faced by the vendors in the Global Cancer Nanomedicine Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Cancer Nanomedicine Market;

3.) The North American Cancer Nanomedicine Market;

4.) The European Cancer Nanomedicine Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

Reasons for Buying this Report:

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecasts 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendixes

Get Up to 20% Discount on this Premium Report @ https://www.globalintelligenceandinsights.com/request-sample-1004167

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Global Intelligence and Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SMEs, start-ups, financial technology start-ups, and venture capitalists. We have an exhaustive database of market research reports provided by more than 20 leading publishers across different industry verticals.

We provide tailored solutions that can be utilized to solve business challenges and problems faced by organizations in different regions. Additionally, our bouquet of solutions assists enterprises in strategic planning and staying ahead of the competition while getting access to extensive market forecast and trend mapping over the future course of time. In addition to the market forecast and other vital components of the market analysis, our reports include in-depth micro-macro analysis of the market, which aids the customers in analyzing the market ecosystem, thus assisting in the existing and new players in the development of strategic plans.

Contact Us:

Global Intelligence Insights

Bruno Abraham

US: +1-571-577-4575

202 Church Street SE,

Suite 301, Leesburg,

VA 20175

[emailprotected]

The rest is here:
Cancer Nanomedicine Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by Forecast 2026 |...

Read More...

Visualization nanozyme based on tumor microenvironment unlocking for intensive combination therapy of breast cancer – Science Advances

Friday, December 4th, 2020

Abstract

Nanozymes as artificial enzymes that mimicked natural enzymelike activities have received great attention in cancer therapy. However, it remains a great challenge to design nanozymes that precisely exert its activity in tumor without producing off-target toxicity to surrounding normal tissues. Here, we report a synergetic enhancement strategy through the combination between nanozyme and tumor vascular normalization to destruct tumors, which was based on tumor microenvironment (TME) unlocking. This nanozyme that we developed not only has photothermal properties but also can produce reactive oxygen species efficiently under the stimulation of TME. Moreover, this nanozyme also showed remarkable imaging performance in fluorescence imaging in the second near-infrared region and magnetic resonance imaging for visualization tracing in vivo. The process of combination therapy showed remarkable therapeutic effect for breast cancer. This study provides a therapeutic strategy by the cooperation between multifunctional nanozyme and tumor vascular normalization for intensive combination therapy of breast cancer.

Breast cancer is the most frequent malignancy in women worldwide and is a heterogeneous disease on the molecular level (1). The heterogeneity of breast cancer tissue usually makes it easy to cause multidrug resistance of tumor, tumor recurrence, or metastasis, which leads to the decline of therapeutic effect (2). The principal reason is that there are differences from genotype to phenotype in the same tumor, resulting in different sensitivity, growth speed, invasion ability, prognosis, and other aspects of tumor cells to drugs (35). A more accurate combination therapy based on tumor heterogeneity could give full play to the maximum effect, produce minimum side effects, and avoid the occurrence of multidrug resistance (68). Recently, combination therapy has been extremely advocated in clinical application. For instance, the simultaneous administration of two or multiple therapeutic agents would modulate different signaling pathways involved in the tumor progression (9, 10), bringing many advantages including synergetic responses, reduced drug resistance, and mitigatory side effects. Therefore, it is of great significance to develop a multimode tumor cooperative therapy system to improve the therapeutic effect of breast cancer.

In the early 1970s, as a young surgeon who frequently encountered cancer in patients, Judah Folkman observed that tumor tissue was enriched by an extraordinarily high number of blood vessels that were fragile and often hemorrhagic (11, 12). The angiogenesis translational research started at that time and has lasted for nearly 50 years. At present, the results show that blocking angiogenesis can retard tumor growth, but it may also increase metastasis paradoxically (13, 14). This issue may be solved by vessel normalization, including increasing pericyte coverage, improving tumor vessel perfusion, reducing the permeability of blood vessels, and mitigating hypoxia consequently (15). Therefore, the normalization of tumor blood vessels is closely related to the regulation of tumor microenvironment (TME). Both humanized monoclonal antibody bevacizumab as the first antivascular endothelial growth factor (VEGF) agents and plasmid expressing interfering RNA targeting VEGF (shVEGF) have been used in cancer therapy (16). In 2017, Zhang elucidated an unexpected role of T helper 1 (TH1) cells in vasculature and immune reprogramming. This finding confirmed that tumor blood vessels and immune system can affect each others functions and proposed that TH1 cells may be a marker and a determinant of both immune checkpoint blockade and anti-angiogenesis efficacy (15). Thus, the combined therapy with tumor vessel normalization is expected to improve the therapeutic effect of breast cancer.

Since Gao et al. (17) reported the first evidence of Fe3O4 nanoparticles (NPs) as peroxidase mimetics in 2007, various nanomaterials have been identified that have intrinsic enzyme-like activities (18, 19). Because of the similar enzymatic kinetics and mechanisms of natural enzymes under physiological conditions, this kind of nanomaterials is called nanozyme (20). The past decade have witnessed the rapid development of nanozymes in biomedical applications including immunoassays, biosensors, antibacterial, and antibiofilm agents (21, 22). Tailored to the specific TME, including the excessive production of acid and hydrogen peroxide, the introduction of highly active nanozyme, through Fenton and Fenton-like reactions to produce reactive oxygen species (ROS), has been used in the chemodynamic therapy (CDT) of cancer (23). A great challenge for in vivo application of nanozyme is the precise control of the selective execution of the desired activity because off-target activity will lead to unpredictable side effects. For instance, Fe3O4 NPs have peroxidase-like activity to increase reactive ROS under acidic pH. However, these NPs exhibit catalase-like activity in neutral condition, which will lead to removal of ROS (24). In the process of ROS-related treatment, the former is beneficial to improve the therapeutic effect, while the latter should be inhibited. Therefore, it is necessary to design a strategy to coordinate the activity of nanozyme through the regulation of TME for optimal functioning upon entering of the nanozyme into its target cell.

As a proof of concept, we have constructed a previously unknown strategy to regulate TME by tumor vessel normalization to optimize the anticancer effect of visualizational nanozyme. Primarily, monodisperse core-shell Ag2S@Fe2C heterogeneous NPs were synthesized by seeded growth-based thermal decomposition method in organic phase. Afterward, to improve the tumor targeting, we designed a precise targeting NP-based nanozyme system (Ag2S@Fe2C-DSPE-PEG-iRGD) by coating a tumor-homing penetration peptidemodified Distearoyl phosphoethanolamine-PEG-iRGD peptide (DSPE-PEG-iRGD) on the surface of Ag2S@Fe2C NPs. This nanozyme showed remarkable intracellular uptake, good fluorescence performance, and up-regulation of ROS production in 4T1 cells. Furthermore, this nanozyme displayed high-resolution bioimaging effect in vivo in 4T1 breast cancerbearing mice, which included fluorescence imaging in the second near-infrared region (NIR-II) and magnetic resonance imaging (MRI). Moreover, the improved therapeutic effect was observed by the treatment of Ag2S@Fe2C-DSPE-PEG-iRGD after combination with the tumor vascular normalization based on bevacizumab during the treatment in 4T1 breast cancerbearing mice. Our study provides a new therapeutic strategy by the cooperation between catalysis of imaging-guided nanozyme and tumor vascular normalization for intensive combination therapy of breast cancer.

The scheme of the combination therapeutic strategy was shown in Fig. 1, including the schematic illustration of combination therapeutic strategy (Fig. 1A) and biochemical process for multifunctional Ag2S@Fe2C-DSPE-PEG-iRGD in breast cancer cell (Fig. 1B). Subsequently, the schematic design of core-shell Ag2S@Fe2C-DSPE-PEG-iRGD is presented in Fig. 2A. First, monodispersed Ag2S@Fe2C NPs were synthesized by seed-mediated growth method with thermal decomposition in organic phase. The synthesis of Ag2S@Fe2C NPs comprises two steps: (i) the preparation of Ag2S quantum dots (QDs) (fig. S1) and (ii) the iron carbide coating on the surface of Ag2S QDs to obtain Ag2S@Fe2C NPs (Fig. 2B). Ag2S QDs were prepared by thermal decomposition of a source precursor of Ag(DDTC) [(C2H5)2NCS2Ag]. (25). Fe2C phase around Ag2S QDs is regulated by ammonium bromide (NH4Br), which has been reported in our previous studies (26, 27). Because the selective adsorption of Br ions weakened the bonding between Fe and C atoms, the process could promote the formation of low-carbon iron carbide phase. Transmission electron microscope (TEM) images in Fig. 2B have shown that Ag2S cores were semisurrounded by the Fe2C domains with a thickness of ~3 nm. The high-resolution TEM (HRTEM) image depicted in Fig. 2C shows a lattice spacing between two (200) adjacent planes in Ag2S of 0.244 nm and distance of 0.209 nm corresponding to the (101) planes of hexagonal Fe2C. Furthermore, energy-dispersive x-ray (EDX) line scan of Ag2S@Fe2C NPs was shown in Fig. 2 (D and E), which has confirmed the composition and core-shell structure of Ag2S@Fe2C NPs. The results of x-ray diffraction (Fig. 2F) patterns were consistent with the characterization of TEM. However, the Fe2C shell was protected from further oxidization by a 1-nm Fe3O4 shell with a spacing of 2.97 between the (220) planes of magnetite. The x-ray photoelectron spectroscopy (XPS) of Fe 2p (Fig. 2G and fig. S2) has confirmed the main existence of Fe0 in Ag2S@Fe2C NPs, and the weak satellite peaks are due to the local oxidation of NPs (26). The existence of Ag+ was confirmed by the XPS of Ag 3d (Fig. 2F and fig. S2). DSPE-PEG-iRGD was synthesized by covalent bonding between DSPE-PEG-NHS (N-hydroxysuccinimide) and tumor-homing penetration peptide iRGD (CRGDKGPDC) subsequently (fig. S3) (28). Ag2S@Fe2C-DSPE-PEG and Ag2S@Fe2C-DSPE-PEG-iRGD were formulated using water/oil (W/O) emulsion method (29). The formation of Ag2S@Fe2C-DSPE-PEG-iRGD nanozyme was confirmed by the Fourier transform infrared spectrometer (fig. S4). The red shift of the absorption peak for the stretching vibration of the CO from carboxyl group (1635 cm1) to amide bond (1689 cm1) proves the amination of DSPE-PEG-NHS and iRGD (fig. S4, i and iv). The existence of vibration absorption peaks (3410 and 1480 cm1) for NH bond (fig. S4, iv) proved the obtaining of DSPE-PEG-iRGD. The hydrodynamic diameters of Ag2S@Fe2C-DSPE-PEG-iRGD were 90.1 20.3 nm (fig. S5A), and the zeta potential of Ag2S@Fe2C-DSPE-PEG-iRGD was 12.2 mV (fig. S5B). The lifetime decays of Ag2S@Fe2C-DSPE-PEG-iRGD ( = 218.16 ns, excitation = 808 nm) were shown in Fig. 2I, which has proved that the NPs exhibit good luminescent property. The field-dependent magnetization curve of Ag2S@Fe2C NPs and Ag2S@Fe2C-DSPE-PEG-iRGD was measured at room temperature. After the modification of DSPE-PEG-iRGD, the magnetic saturation value is reduced from 116.97 to 50.12 electromagnetic unit (emu) g1 (fig. S5C). This result proves that Ag2S@Fe2C-DSPE-PEG-iRGD can be used as contrast agent in T2-MRI. Besides, better absorption capacity for light in the NIR was observed in Ag2S@Fe2C-DSPE-PEG-iRGD compared to Ag2S@Fe2C in fig. S5D.

(A) Schematic illustration of combination therapeutic strategy. (B) Schematic diagram of biochemical process for multifunctional Ag2S@Fe2C-DSPE-PEG-iRGD in breast cancer cell. PTT, photothermal therapy.

(A) Schematic illustration of the designed Ag2S@Fe2C-DSPE-PEG-iRGD core-shell heterojunctions. (B) TEM image of Ag2S@Fe2C NPs. (C) HRTEM image of Ag2S@Fe2C NPs. (D and E) EDX line scan of Ag2S@Fe2C NPs: Fe (blue), Ag (red), and S (black). (F) X-ray diffraction patterns of Ag2S@Fe2C NPs. High-resolution XPS spectra of (G) Fe 2p and (H) Ag 3d obtained from Ag2S@Fe2C. (I) Lifetime decays of Ag2S@Fe2C-DSPE-PEG-iRGD (excitation = 808 nm). a.u., arbitrary units.

The biodegradation performance of Ag2S@Fe2C-DSPE-PEG was evaluated by time-dependent fluorescence spectra in 48 hours (Fig. 3A). With the prolongation of dispersion time of Ag2S@Fe2C-DSPE-PEG in phosphate-buffered saline (PBS) buffer (pH 5.4). The fluorescence intensity increases with time at the emission wavelength of 410 nm, which has demonstrated that carbon QDs (C QDs) are produced during the degradation of Ag2S@Fe2C-DSPE-PEG (30). The fluorescence spectra of Ag2S@Fe2C-DSPE-PEG were dispersed in PBS buffer (pH 7.4), and PBS buffer (pH 5.4) after 7 days further confirmed the stability of pH-dependent Ag2S@Fe2C-DSPE-PEG in fig. S6A. Subsequently, the evaluation of peroxidase-like activity of Ag2S@Fe2C-DSPE-PEG with different pH values was shown in Fig. 3B and fig. S6B. The peroxidase-like activity increases with the decrease of pH value. Moreover, TEM images of the Ag2S@Fe2C-DSPE-PEG after degradation in PBS with pH value of 5.4 in 48 hours was revealed in Fig. 3C. After 6 hours, the NPs maintain the integrity generally with only slight morphological changes (arrow indicated). After 24 hours, degradation occurred in most of NPs from morphology and size. In addition, the free state of Ag2S QDs can be observed in the TEM image. After 48 hours, the morphology of the NPs is completely disrupted and residues of the C QDs can be observed (arrow indicated). Since C QDs and graphene oxide (GO) have a similar structure, the fluorescence property can be determined by the states of the sp2 sites (31). Moreover, the samples that were obtained from Ag2S@Fe2C NP degradation in HCl solution (1 M) before and after 12 hours (fig. S7A) were characterized by XPS (fig. S7B). Normalized high-resolution XPS spectra of C 1s proved the existence of low-valence carbon. Moreover, as shown in fig. S7C, the carbon K edge spectrum of samples collected above shows a clear sp2 signal with energy loss peaks at 283 eV (1s *) and 293 eV (1s *), which proved the existence of sp2-hybridized carbon in Ag2S@Fe2C NPs (32). Therefore, we can infer that these sp2-hybridized carbons were obtained during the thermal decomposition synthesis of Ag2S@Fe2C NPs. To further prove the above speculation, the biodegradation behavior and structural evolution of Ag2S@Fe2C-DSPE-PEG were further evaluated in 4T1 cells. After 24 hours of intracellular coincubation, Ag2S@Fe2C-DSPE-PEG was almost degraded into ultrasmall NPs. These results were exhibited in bio-TEM images in Fig. 3D.

(A) Time-dependent fluorescence spectra of Ag2S@Fe2C-DSPE-PEG dispersed in PBS buffer solution (pH 5.4, excitation = 370 nm, Em = 410 nm). (B) Peroxidase-like activity of Ag2S@Fe2C-DSPE-PEG with different pH values (5.4, 6.5, and 7.4). Photo credit: Zhiyi Wang, Peking University, China. (C) TEM images (scale bars, 50 nm) of the Ag2S@Fe2C-DSPE-PEG after degradation in PBS (pH 5.4) for 0, 6, 24, and 48 hours. (D) Bio-TEM images (scale bar, 2 m) of 4T1 cells incubated with Ag2S@Fe2C-DSPE-PEG for 24 hours (scale bars, 500 nm) of different regions enlarged. (E) Schematic representation of the degradation process of the Ag2S@Fe2C-DSPE-PEG in the physiological environment.

On the basis of the above experimental results, Fig. 3E illustrated the degradation process of Ag2S@Fe2C-DSPE-PEG. The external DSPE-PEG degraded gradually because of hydrolysis of the ester linkage into segments (reduced molecular weight), oligomers and monomers, and lastly carbon dioxide and water (33) after the Ag2S@Fe2C-DSPE-PEG were dispersed in the physiological environment. Degradation of DSPE-PEG disrupts the NPs and triggers release of Fe2+ and C QDs from the Fe2C shell, which degrades rapidly if it is not protected by DSPE-PEG. After the degradation of Fe2C shell, Ag2S QDs were commonly found in bio-TEM images. Because the C QDs and Ag2S QDs are relatively stable in physiological environment, it is beneficial to be metabolized out of the body through the kidney and liver (34, 35). The unique biodegradability of the Ag2S@Fe2C-DSPE-PEG not only circumvents rapid degradation of the optical performance but also enables harmless clearance from the body in a reasonable period after the end of therapeutic functions in vivo.

The modification by DSPE-PEG-iRGD enhanced the biocompatibility of NPs under physiological conditions, which was proved by cell counting kit-8 (CCK8) assay in fig. S8. The cellular uptake of Ag2S@Fe2C-DSPE-PEG-iRGD in 4T1 cells was evaluated by multidimensional confocal microfluorescence imaging system in Fig. 4A (excitation = 808 nm). These results revealed that a minority of red fluorescence could be observed in 4T1 cells treated with Ag2S@Fe2C-DSPE-PEG, indicating the limited cellular uptake. However, much stronger red fluorescence could be found after coincubation with Ag2S@Fe2C-DSPE-PEG-iRGD, which is mainly located in cytoplasm, instead of nuclei [staining by 4,6-diamidino-2-phenylindole (DAPI), excitation = 405 nm]. These results suggested that the Ag2S@Fe2C-DSPE-PEG-iRGD performed higher cellular uptake after the modification with tumor-homing penetration peptide iRGD.

Subsequently, we further evaluated the nanozyme activity of Ag2S@Fe2C-DSPE-PEG-iRGD in cancer cells. Because nonfluorescent dihydrorhodamine 123 (DHR123) can be oxidized by ROS into green fluorescent rhodamine 123, DHR123 was used as an intracellular ROS indicator (36). Fortunately, the strongest fluorescence intensity was shown in the group of Ag2S@Fe2C-DSPE-PEG-iRGD under the irradiation of 808-nm laser, which demonstrated that the nanozyme activity of Ag2S@Fe2C-DSPE-PEG-iRGD was also enhanced compared with other groups (Fig. 4B). In the previous study, we reported the evaluation method of photothermal efficiency of nanomaterials (27, 37, 38). These results in fig. S11 demonstrated that Ag2S@Fe2C-DSPE-PEG-iRGD is a highly efficient photothermal therapy agent. The 4T1 cell killing ability was evaluated in fluorescence micrographs in Fig. 4C [costained by calcein-AM and propidium iodide (PI)]. The group of Ag2S@Fe2C-DSPE-PEG-iRGD under the irradiation of 808-nm laser showed the maximum range of dead cell markers, which proved that it has the strongest killing efficiency of 4T1 cells. Furthermore, corresponding flow cytometry data of the 4T1 cells stained with PI (dead cells, red fluorescence) was shown in Fig. 4D after incubation with saline only, the irradiation of 808-nm laser only, Ag2S@Fe2C-DSPE-PEG-iRGD, and Ag2S@Fe2C-DSPE-PEG-iRGD under the irradiation of 808-nm laser. These results are consistent with above.

(A) Confocal laser scanning microscopy images (scale bars, 5 m) of in 4T1 cells treated with saline, Ag2S@Fe2C-DSPE-PEG, and Ag2S@Fe2C-DSPE-PEG-iRGD in NIR-II. (B) Singlet oxygen generation evaluated by DHR123 in 4T1 cells treated with saline only, laser only, Ag2S@Fe2C-DSPE-PEG, and Ag2S@Fe2C-DSPE-PEG + laser (scale bars, 50 m). (C) Fluorescence images (scale bars, 100 m) of the 4T1 cells stained with calcein-AM (live cells, green fluorescence) and PI (dead cells, red fluorescence) after incubation with saline only, laser only, Ag2S@Fe2C-DSPE-PEG, and Ag2S@Fe2C-DSPE-PEG + laser. (D) Corresponding flow cytometry data of the 4T1 cells stained with PI (dead cells, red fluorescence) after incubation with saline only, laser only, Ag2S@Fe2C-DSPE-PEG, and Ag2S@Fe2C-DSPE-PEG + laser.

The fluorescent emission spectrum of Ag2S@Fe2C and Ag2S@Fe2C-DSPE-PEG-iRGD in NIR-II was shown in Fig. 5A. Under the excitation of 808-nm laser, the fluorescent emission wavelength is 1071 nm. Subsequently, fluorescence imaging in NIR-II was carried out to track the in vivo behaviors of Ag2S@Fe2C-DSPE-PEG and Ag2S@Fe2C-DSPE-PEG-iRGD (20 mg kg1, 200 ml) after intravenous injection into 4T1 breast cancerbearing nude mice, with the excitation wavelength of 808 nm (Fig. 5B). The tumor site of Ag2S@Fe2C-DSPE-PEG-iRGD group showed strong luminescence signals after 12 hours (Fig. 5C). In contrast, no obvious fluorescence signal appeared in the tumor site for Ag2S@Fe2C-DSPE-PEG even after 24 hours. Moreover, the targeting capacity of Ag2S@Fe2C-DSPE-PEG and Ag2S@Fe2C-DSPE-PEG-iRGD was evaluated by ex vivo imaging of main organs (liver, spleen, lung, heart, and kidney) and tumors of mice after intravenous injection for 24 hours. Obvious fluorescence signals were clearly observed in the liver, tumor, and the main blood vessels near the tumor (Fig. 5B). The real-time movie of fluorescence imaging in NIR-II has been improved during the tail vein injection of Ag2S@Fe2C-DSPE-PEG-iRGD (movie S1), which demonstrated that the nanozyme could achieve high-resolution microscopic imaging of blood vessels in mice, especially at the tumor site. These results reflect not only the advantages of fluorescence imaging in NIR-II with deeper tissue penetration but also the remarkable targeting effect of the Ag2S@Fe2C-DSPE-PEG-iRGD for 4T1 breast cancer.

(A) The fluorescent emission spectrum of Ag2S@Fe2C and Ag2S@Fe2C-DSPE-PEG-iRGD in NIR-II under the excitation of 808-nm laser. (B) Real-time NIR-II fluorescence images of 4T1 breast cancerbearing mice after intravenous injection of Ag2S@Fe2C-DSPE-PEG and Ag2S@Fe2C-DSPE-PEG-iRGD. Ex vivo fluorescence images of heart (i), kidney (ii), spleen (iii), liver (iv), lung (v), and tumor (vi), which were obtained at 48 hours after injection. Photo credit: Zhiyi Wang, Peking University, China. (C) The fluorescence intensities of the tumor after intravenous injection of Ag2S@Fe2C-DSPE-PEG and Ag2S@Fe2C-DSPE-PEG-iRGD, respectively. (D) T2 relaxation rate (1/T2) as a function of Fe concentration for the Ag2S@Fe2C-DSPE-PEG-iRGD. (E) Real-time MRI of 4T1 breast cancerbearing mice after intravenous injection of Ag2S@Fe2C-DSPE-PEG and Ag2S@Fe2C-DSPE-PEG-iRGD. (F) The relative MRI signal intensities changing at the tumor site after intravenous injection of Ag2S@Fe2C-DSPE-PEG and Ag2S@Fe2C-DSPE-PEG-iRGD, respectively. (G) The wide-field images show the Ag2S@Fe2C-DSPE-PEG-iRGD luminescence signals in liver and spleen at 1 and 14 days. (H) The excretion of Ag2S@Fe2C-DSPE-PEG-iRGD from mouse liver and spleen can be seen by plotting the signal intensity in these organs (normalized to liver signal observed at 1 day) as a function of time over 2 weeks. (I) Biodistribution of Ag2S@Fe2C-DSPE-PEG-iRGD in main organs and feces of Ag2S@Fe2C-DSPE-PEG-iRGDtreated mice at 14 days. Error bars, means SD (n = 3).

After calculation, the r2 value of Ag2S@Fe2C-DSPE-PEG was around 127.9 mM1 s1 when dispersed in water (Fig. 5D). Furthermore, we assessed the T2-weighted MRI capability in vivo after intravenous injection of Ag2S@Fe2C-DSPE-PEG and Ag2S@Fe2C-DSPE-PEG-iRGD (20 mg kg1, 200 ml) into 4T1 breast cancerbearing nude mice. Figure 5E clearly indicates that the Ag2S@Fe2C-DSPE-PEG-iRGD show stronger signal intensity and make the tumor darker than Ag2S@Fe2C-DSPE-PEG after 24 hours of injection. These results suggest higher accumulations of Ag2S@Fe2C-DSPE-PEG-iRGD at the tumor sites owing to the active targeting by tumor-homing penetration peptide iRGD. Therefore, Ag2S@Fe2C NPs have the potential to be the agents for T2-weighted MRI.

The luminescence signal intensity in the main organs of mice, including liver and spleen, kept decreasing within the monitored time period of 14 days (Fig. 5, G and H). All the urine and feces excreted from mice were collected, and Ag was quantitatively detected by inductively coupled plasma optical emission spectrometry, revealing that ~90% of injected Ag2S@Fe2C-DSPE-PEG-iRGD was excreted from the body in 14 days (Fig. 5I). This rapid, high-degree excretion could promote clinical translation of Ag2S@Fe2C-DSPE-PEG-iRGD.

As mentioned before, angiogenesis as a physiologically complex process of proliferation and migration of endothelial cells could be suppressed by bevacizumab, which will benefit more for the tumor vascular normalization. We evaluated angiogenesis suppression effect of murine bevacizumab by fluorescence imaging in NIR-II and immunohistochemical analysis of CD31. Figure 6A showed the experimental diagram of 4T1 breast cancer angiogenesis by bevacizumab, which was imaged in NIR-II by intraperitoneal injection of low-dose Ag2S@Fe2C-DSPE-PEG-iRGD in 4T1 breast cancerbearing mice. Comparing to the group of saline injection, tumor angiogenesis inhibition effect by bevacizumab was demonstrated in the tumor site in the first 10 days (Fig. 6, B and C, and fig. S10). Then, tumor grew rapidly. Furthermore, the real-time movie of fluorescence imaging in NIR-II was provided in 0 and 20 days for each group (movies S2 to S5). These results also proved that bevacizumab cannot be used as a single drug for tumor. Moreover, CD31 immunohistochemical staining of harvested 4T1 tumor after 20 days was shown in Fig. 6D. We can clearly observe that the tumor vascular density in bevacizumab injection group is notably less than the control group, which is consistent with fluorescence imaging results. Therefore, bevacizumab could influence the tumor vascular normalization of 4T1 breast cancer.

(A) Schematic illustration of self-monitoring for inhibition of tumor angiogenesis by Ag2S@Fe2C-DSPE-PEG-iRGD after intraperitoneal injection of saline and bevacizumab. (B) Real-time NIR-II fluorescence images of 4T1 breast cancerbearing mice after intraperitoneal injection of normal saline and bevacizumab by Ag2S@Fe2C-DSPE-PEG-iRGD. (C) Representative photograph for volume change of tumor after intraperitoneal injection of normal saline and bevacizumab in 20 days. Inset: Corresponding harvested 4T1 breast cancer after 20 days. Photo credit: Zhiyi Wang, Peking University, China. (D) CD31 immunohistochemical staining of harvested 4T1 breast cancer after 20 days. Error bars, means SD (n = 5).

Combination therapy (i.e., photothermal therapy, CDT, and tumor vascular normalization) was investigated by treatment of 4T1 breast cancerbearing mice in vivo. Figure 7A showed the schematic illustration of the therapy process. When laser irradiation is applied to Ag2S@Fe2C-DSPE-PEG-iRGDinjected mice, the local temperature of the tumor site rapidly increases from 37 to 54.7C within 5 min, but for the mice treated with Ag2S@Fe2C-DSPE-PEG, the temperature only reaches to 46.8C (Fig. 7B and fig. S10A). These results confirmed the superior targeting capability of Ag2S@Fe2C-DSPE-PEG-iRGD, which is consistent with the above results of bioimaging. Furthermore, the biodistribution of Ag after intravenous injection for 3 days was detected by inductively coupled plasma mass spectrometry, which confirmed the targeting capacity of Ag2S@Fe2C-DSPE-PEG-iRGD in vivo (fig. S10B). Comparing with other groups, the remarkable antitumor efficiency of Ag2S@Fe2C-DSPE-PEG-iRGD was demonstrated by tumor volume with significant inhibition and elimination in vivo (Fig. 7, C and D, and fig. S10C). The growth status of representative nude mice in each group at the time interval of 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30 days throughout the treatment period was observed (Fig. 7C and fig. S10D). The tumor of harvested mice injected with Ag2S@Fe2C-DSPE-PEG-iRGD and bevacizumab under the laser irradiation (808 nm, 0.3 W cm2) was completely eradicated after treatment. An obvious damage was evidenced to the tumor cells of mice by cell necrosis and apoptosis in the group of injection with Ag2S@Fe2C-DSPE-PEG-iRGD and bevacizumab after laser irradiation. Mice treated with other groups showed less necrotic areas (Fig. 7E). These results showed that Ag2S@Fe2C-DSPE-PEG-iRGD was an efficient nanozyme as targeting nanomaterials with antitumor capacity in 4T1 breast cancerbearing mice.

(A) Schematic illustration of Ag2S@Fe2C-DSPE-PEG-iRGD nanocapsule-based tumor therapy. (B) Real-time thermal infrared images of 4T1 breast cancerbearing mice after intravenous injection of saline, Ag2S@Fe2C-DSPE-PEG + laser, Ag2S@Fe2C-DSPE-PEG + laser + bevacizumab, Ag2S@Fe2C-DSPE-PEG-iRGD + laser, and Ag2S@Fe2C-DSPE-PEG-iRGD + laser + bevacizumab under 808-nm laser irradiation (0.3 W cm2, 5 min). (C) Representative photograph for volume change of tumor in the different treatments in 30 days. Photo credit: Zhiyi Wang, Peking University, China. (D) Volume change of tumor in the different treatments. (E) H&E-stained images of tumor regions with different treatments. Error bars, means SD (n = 5), unpaired t test.

Subsequently, toxicity analysis of these NPs was investigated in vivo. There was no decrease in the weight of the mice in each group during the treatment, which demonstrates the low toxicity of the Ag2S@Fe2C-DSPE-PEG-iRGD (fig. S10C). The histological analysis was done by hematoxylin and eosin (H&E) staining of the main organs after the treatment to study the damage in acute and chronic stages. No tissue necrosis was observed in the main organs (heart, liver, spleen, lung, and kidney) for the seven groups (fig. S12), demonstrating that the Ag2S@Fe2C-DSPE-PEG-iRGD have no significant side effects in vivo.

The complicated TME has brought great challenge to the therapeutic effect of nanomedicine for a long time. As mentioned above, it is almost impossible for specific nanoagents to penetrate the tumor through targeted effect to achieve effective accumulation and cell uptake and then excrete through metabolism after treatment. To overcome the multiple biological barriers during the drug delivery, nanomedicine should be rationally designed. In this work, a precise targeting NP-based nanozyme system (Ag2S@Fe2C-DSPE-PEG-iRGD) was developed for theranostics of breast cancer. At the cellular level, the nanozyme showed the efficient capacity of cell uptake and ROS production. In addition, this nanozyme has developed prominent luminescence in NIR-II and MRI contrast properties, which will be helpful to the visual tracking in vivo. As a result, the improved therapeutic effect was observed by the treatment of Ag2S@Fe2C-DSPE-PEG-iRGD after combination with the tumor vascular normalization based on bevacizumab during the treatment in 4T1 breast cancerbearing mice. Furthermore, ~90% of injected Ag2S@Fe2C-DSPE-PEG-iRGD was excreted from the body in 14 days. This rapid, high-degree excretion could promote clinical translation of Ag2S@Fe2C-DSPE-PEG-iRGD. Hence, this study presents a new therapeutic strategy by the cooperation between catalysis of smart nanozyme system and tumor vascular normalization for intensive combination therapy of breast cancer, which would accelerate exploitation and clinical translation of nanomedicine.

Ag2S@Fe2C NPs were synthesized by a facile seed-mediated growth method. First, Ag2S QDs were synthesized following our previously reported method. In the typical synthesis, Ag2S QDs (10 mg liter1 in hexane, 1 ml), 1-octadecene (ODE) (62.5 mmol), NH4Br (0.1 mmol), and Oleamine (OAm) (1 mmol) were mixed under a gentle N2 flow for 30 min in a four-necked flask. Then, the solution was heated to 120C and kept for 30 min to remove the organic impurities. Fe(CO)5 (5 mmol) was injected into the reaction system when the temperature reached 180C and kept for 10 min, and the system was raised up to 300C for another 30 min. After the system cooled down to room temperature, 27 ml of acetone was added to the system. After centrifugation, the product was washed by ethanol and hexane.

Ag2S@Fe2C-DSPE-PEG was formulated using W/O emulsion method. Typically, DSPE-PEG-NH2 (250.0 mg, 0.05 mmol) was dissolved in 12 ml of deionized water. Subsequently, Ag2S@Fe2C NPs (10 mg ml1 in dichloromethane, 3 ml) was added to the system. Then, the mixed system was kept for 10 min by using ultrasound. The organic solvent in the obtained W/O emulsion was evaporated using a rotary evaporator at 25C for 2 hours. Ag2S@Fe2C-DSPE-PEG was obtained after centrifugation at 10,000g for 10 min. This synthesized Ag2S@Fe2C-DSPE-PEG was dispersed in PBS buffer (pH 7.4) for further use. Ag2S@Fe2C-DSPE-PEG-iRGD was synthesized by using the same method as Ag2S@Fe2C-DSPE-PEG; the only difference was the addition of DSPE-PEG-iRGD.

The cell LIVE/DEAD assays were also studied to investigate photothermal therapy in vitro. The 4T1 cells grown to 80% confluence in glass bottom 24-well plate were incubated with Ag2S@Fe2C-DSPE-PEG for 4 hours, respectively. After washing the free NPs with Dulbeccos Phosphate-Buffered Saline (DPBS), fresh culture medium was added. Laser (808 nm, 0.3 W cm2) was used to irradiate the adherent cell solution. After the Dulbeccos modified Eagle medium was removed, the cells were washed with PBS three times. Calcein-AM (100 l) and PI solution (100 l) were incubated with 4T1 cells for 15 min. Living cells were stained with calcein-AM (green fluorescence), and dead cells were stained with PI (red fluorescence) solution. The cells were then visualized using an inverted microscope (Olympus IX71) with a 10 under laser excitation at 475 and 542 nm.

Mice bearing 200-mm3 4T1 breast cancer were randomly divided into nine groups: (i) Ag2S@Fe2C-DSPE-PEG-iRGD, laser irradiation, and bevacizumab; (ii) Ag2S@Fe2C-DSPE-PEG-iRGD and laser irradiation; (iii) Ag2S@Fe2C-DSPE-PEG, laser irradiation, and bevacizumab; (iv) Ag2S@Fe2C-DSPE-PEG-iRGD and laser irradiation; (v) Ag2S@Fe2C-DSPE-PEG-iRGD; (vi) Ag2S@Fe2C-DSPE-PEG; (vii) bevacizumab; (viii) laser irradiation only; and (ix) control (only saline). Nine mice were contained in each group. After 200 ml of saline or NPs (20 mg kg1) were intravenously injected into nude mice bearing the 4T1 breast cancer for 24 hours, mice were exposed to 808-nm laser (0.3 W cm2) for 5 min and tail veininjected with bevacizumab. The changes of body weight and tumor volume during 30 days of treatment period were recorded.

Immunohistochemical was stained using anti-CD31 antibody, according to the corresponding protocols. Mice from each group were euthanized; then, major organs and tumor were recovered, followed by fixing with 10% neutral-buffered formalin after 18-day treatment. The organs were embedded in paraffin and sectioned at 5 mm. H&E or Prussian blue staining was performed for histological examination. The slides were observed under an optical microscope.

All data are expressed as means SD. Statistical differences were determined by two-tailed Students t test; *P < 0.05, **P < 0.01, and ***P < 0.001.

All experiments involving animals were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Peking University, Beijing, China.

Acknowledgments: Funding: This work was supported by the Natural Science Foundation of Beijing Municipality (L72008), the National Natural Science Foundation of China (51672010, 81421004, 51631001, 51590882, and 51602285), the National Key R&D Program of China (2017YFA0206301 and 2016YFA0200102), the Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences (NSKF201607), and China Postdoctoral Science Fund (2019M660315). Author contributions: Z.W. and Y.H. conceived and designed the experiments. Z.W., Z.L., Z.S., S.L., S.Z., S.W., Q.R., and F.S. performed the experiments. Z.W. and Y.H. analyzed the results. Z.W., Z.A., B.W., and Y.H. wrote and revised the manuscript. Z.W. and Y.H. supervised the entire project. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Read more:
Visualization nanozyme based on tumor microenvironment unlocking for intensive combination therapy of breast cancer - Science Advances

Read More...

Nanomedicine Market 2019 Global Outlook, Research, Trends and Forecast to 2025 – The Haitian-Caribbean News Network

Friday, December 4th, 2020

Nanomedicine Market Forecast 2020-2026

The Global Nanomedicine Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Nanomedicine Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/11972

The Report Covers the Following Companies:CombimatrixAblynxAbraxis BioscienceCelgeneMallinckrodtArrowhead ResearchGE HealthcareMerckPfizerNanosphereEpeius BiotechnologiesCytimmune SciencesNanospectra Biosciences

By Types:Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices

By Applications:Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/11972

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Nanomedicine Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/11972

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Organization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

Read this article:
Nanomedicine Market 2019 Global Outlook, Research, Trends and Forecast to 2025 - The Haitian-Caribbean News Network

Read More...

Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) – The Media Line

Friday, December 4th, 2020

Tel Aviv University researchers use tiny molecular scissors to target aggressive metastatic cancer cells

Israeli scientists have developed a cutting-edge nanotechnology system that can destroy cancerous cells in mice.

The Tel Aviv University team of researchers pioneered a treatment method that is so precise, it is almost as if tiny molecular scissors were being used to kill the cancer.

We developed a delivery system for these molecular scissors that can specifically reach tumor cells while leaving normal cells intact, Dr. Daniel Rosenblum, a postdoctoral fellow from the Laboratory of Precision NanoMedicine at the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University, told The Media Line.

By cutting their DNA in specific genes that are responsible for cell division or cell survival, we basically neutralize them and they die from the treatment, he said. The system we developed is based on the Cas9 CRISPR protein in a [messenger] RNA format.

The process, known as CRISPR genome editing, allows researchers to alter DNA sequences. Specifically, scientists at the university created what is known as CRISPR-LNPs, a lipid nanoparticle delivery system that carries a genetic messenger (known as messenger RNA), along with a navigation system that can recognize cancerous cells.

The findings of the peer-reviewed research were published last month in the Science Advances journal.

This is the first study in the world to prove that the CRISPR genome editing system can be used to treat cancer in a living animal effectively,said Prof. Dan Peer, vice president for Research and Development at Tel Aviv University and head of TAUs Laboratory of Precision NanoMedicine.

The idea there is to take the cells from the patients, edit them in a plate outside the body and then inject them back into the patient, he told The Media Line. We believe that this could be expanded to much more than just the two models that we have tried.

So far, researchers at Tel Aviv University have tested the technology on mice and have observed no adverse reactions. This stands in contrast to chemotherapy, which kills both cancerous and healthy cells.

The CRISPR-LNPs were tested on glioblastoma tumors, an extremely aggressive type of brain cancer that has a five-year survival rate of only 3%. In addition, the researchers tested the system on metastatic ovarian cancer, a major cause of death among women and the most lethal cancer in the female reproductive system.

Wake up to the Trusted Mideast News source Mideast Daily News Email

For the glioblastoma tumors, the treatment was found to double the average life expectancy of mice and improve their overall survival rate by about 30%. For ovarian cancer, the overall survival rate rose by a whopping 80%.

When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried

We envision that we can simply inject [the treatment] into the body and because of the GPS they can find their way to the tumor, Anna Gutkin, a doctoral student in the laboratory, told The Media Line. We encountered several hurdles in the development of this technology but its exciting to work on this. It really opens new avenues for us to develop novel therapies.

Aside from its potentially revolutionary impact on future cancer treatments, the technology also opens the door for treating rare genetic diseases and viral diseases such as AIDS, according to the researchers. A similar technology based on messenger RNA currently is being used by Pfizer (BioNTech) and Moderna for their COVID-19 vaccines.

Our system is a bit more sophisticated both from the materials they are created from [and] we also gave it a GPS system, which is pretty unique, Rosenblum noted.

In the future, Peer and his team hope to test the groundbreaking technology on larger animal models. Human trials are expected to begin in about two years.

Because of the coronavirus crisis we have witnessed how fast new approaches could be translated into the clinic, Peer said.

When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried, he concluded.

Read the original here:
Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) - The Media Line

Read More...

Nanomedicine Market 2020 by Industry Growth And Competitive Landscape Trends, Segmentation SRI International (US), Aditech Ltd. (UK), Anviz Global,…

Friday, December 4th, 2020

Introduction:

This exclusive research report on global Nanomedicine market initiated by Orbis Pharma Reports is an demonstrative replica of diverse market relevant factors dominant across historical and current timelines. The report is anticipated to aid market players willing to upscale their business models and ROI. The report carries out a deep analytical study to identify and understand the potential of core factors that stimulate high end growth. In this report, expert research analysts at Orbis Pharma Reports categorically focus on the pre and post pandemic market conditions to equip readers with ample cues on market progression based on which frontline vendors and other contributing players can successfully design and deploy accurate business decisions and apt growth strategies to secure a healthy footing amidst stringent market competition, fast transitioning regulatory framework and vendor preferences.

Get sample copy of Nanomedicine Market report @ https://www.orbispharmareports.com/sample-request/81199

Major Company Profiles operating in the Nanomedicine Market:

CIC biomaGUNESwedNanoTechBiotechrabbitChemConnectionLTFNAffilogicIstec CNREndomagneticsCarlina technologiesVicomtechVITO NVGrupo PraxisCIBER-BBNGIMACTecnaliaBraccoCristal TherapeuticsTeknikerFraunhofer ICT-IMMBergmannstrostMaterials Research CentreContiproDTIIMDEA

Scope:

The report also includes specific details on core developments such as pricing strategies and manufacturer investments towards selecting growth appropriate business decisions, understanding core methodologies, market size, dimensions as well as share, and market CAGR inputs and investments that collectively illuminate growth favorable route in global Nanomedicine market.Based on market research endeavors and gauging into past growth milestones, seasoned in-house researchers at Orbis Pharma Reports are suggesting an impressive comeback of global Nanomedicine market, significantly offsetting the implications of the global pandemic and its aftermath.

Browse the complete report @ https://www.orbispharmareports.com/global-nanomedicine-market-report-2019-competitive-landscape-trends-and-opportunities/

Nanomedicine Market Product Type:

Type 1Type 2Type 3

Nanomedicine Market Application:

Application 1Application 2Application 3

Segmentation by Type and ApplicationThe end-use application segment is thoroughly influenced by fast transitioning end-user inclination and preferences. Product and application-based segments clearly focus on the array of novel changes and new investments made by market forerunners towards improving product qualities to align with end-use needs. Additionally, this report by Orbis Pharma Reports also includes a dedicated section on various categorization of the market based on product type and diversification. Each of the product and service offerings are maneuvered to undergo rapid transitions to improve growth scope and investment returns in the coming years.

Report Offerings in a Gist:

1.The report by Orbis Pharma Reports outlines crucial attributes of the global Nanomedicine market with detailed understanding of major innovations and events, also highlighting growth plot chalked by leading players2.A decisive overview of macro and micro economic factors have also been highlighted in the report to understand major influences and drivers3.An in-depth impression of crucial technological milestones and a value-based and volume-based output of the same have also been pinned in the report.4.Rife predictions on segment performance and opportunity analysis have also been minutely addressed in the report to decipher growth process and futuristic possibilities.

For Any Query on the Nanomedicine Market: https://www.orbispharmareports.com/enquiry-before-buying/81199

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

Read more from the original source:
Nanomedicine Market 2020 by Industry Growth And Competitive Landscape Trends, Segmentation SRI International (US), Aditech Ltd. (UK), Anviz Global,...

Read More...

Global Nanomedicine Market Top Countries Analysis and Manufacturers With Impact of COVID-19 | 2020-2026 Detail Analysis focusing on Application, Types…

Wednesday, November 25th, 2020

Databridgemarketresearch.com Present Global Nanomedicine Market Industry Trends and Forecast to 2027 new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. This Global Nanomedicine Market report takes into consideration diverse segments of the market analysis that todays business ask for. The Global Nanomedicine Market report provides estimations of CAGR values, market drivers and market restraints about the industry which are helpful for the businesses in deciding upon numerous strategies. The base year for calculation in the report is taken as 2017 whereas the historic year is 2016 which will tell you how the Global Nanomedicine Market is going to perform in the forecast years by informing you what the market definition, classifications, applications, and engagements are. The report helps you to be there on the right track by making you focus on the data and realities of the industry.

The research studies of this Global Nanomedicine Market report helps to evaluate several important parameters that can be mentioned as investment in a rising market, success of a new product, and expansion of market share. Market estimations along with the statistical nuances included in this market report give an insightful view of the market. The market analysis serves present as well as future aspects of the market primarily depending upon factors on which the companies contribute in the market growth, crucial trends and segmentation analysis. This Global Nanomedicine Market research report also gives widespread study about different market segments and regions.

Global nanomedicine marketis registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global nanomedicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/request-a-discount/global-nanomedicine-market

Market Segmentation:-

By Product Type

By Application

By Indication

By Modality

To comprehend Global Nanomedicine market dynamics in the world mainly, the worldwide Nanomedicine market is analyzed across major global regions.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Here is the original post:
Global Nanomedicine Market Top Countries Analysis and Manufacturers With Impact of COVID-19 | 2020-2026 Detail Analysis focusing on Application, Types...

Read More...

Page 11234..10..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick